knowledge -WSS

knowledge

author：leisure time 2025-08-11 09:46:18 - browse：2

European Medicines Agency Suffers Cyber Attack in Amsterdam — Paulo Amorim / VWPics via AP Images

LONDON — This week, European regulators are considering an appeal from Amylyx Pharmaceuticals after initially recommending against approving the company’s ALS treatment — the latest potential turning point for a drug that has seen its share of ups and downs with regulatory bodies.

In June, a European Medicines Agency committee issued a negative review of Amylyx’s drug, called Albrioza, and cast doubt on whether it had demonstrated effectiveness in its pivotal study. That would have almost certainly led to a rejection by regulators, but Amylyx requested what’s called a re-examination of the opinion. On Tuesday, the EMA held a meeting on the appeal, and a decision is expected in the coming weeks.

“There are patients who are dying and they really want access to the drug,” said Evy Reviers, the chairwoman of the European Organization for Professionals and Patients with ALS, whose father has the neurological disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： RaDonda Vaught to speak at CommonSpirit event on patient safety

focus

WSS

How should state employee insurance handle Wegovy?

Massive project maps cells in human brain in unprecedented detail

European regulators recommend Amylyx's ALS drug be rejected

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

House looks to weaken Medicare negotiation

Medicare to cover more brain scans related to Alzheimer’s drugs

Wikipedia

knowledge

explore

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

After affirmative action ruling, medical educators look to 'holistic review'

FDA does about

Supreme Court strikes down use of affirmative action

Why getting cancer drugs just got harder for rural patients

Medical records are filled with copy

Female surgeons have lower rates of long

Activists slam private health insurers over coverage restrictions

Change Healthcare cyberattack outage could last weeks

explore

Nick Jonas talks about managing diabetes along with his career

AstraZeneca loses challenge to Medicare drug price negotiation

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

European regulators consider appeal over Amylyx ALS drug

FogPharma raises $145 million in rare Series E round

FogPharma raises $145 million in rare Series E round

focus

focus

focus

explore